semaglutide
Commercial- Indications
- obesity, weight management
Company intelligence / Profile preview
Noom offers a digital-first healthcare platform focused on sustainable weight loss, obesity treatment—including GLP‑1 medication support—and type 2 diabetes prevention. Its approach combines psychology-driven behavior change with clinical care when needed. The company’s programs have demonstrated significant outcomes in published studies—for example, sustained weight loss after two years for many users and reduced risk of type 2 diabetes in at-risk populations. The Diabetes Prevention Program was the first mobile solution to receive CDC recognition.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Noom.